Spruce Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview

Spruce Biosciences

09/08/2024 16:52

* Spruce Biosciences Inc  SPRB.OQ   SPRB.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 12
(estimated) for the period ending June 30 2024
    * The South San Francisco California-based  company is
expected to
report a 30.9% decrease in revenue to $1.495 million from $2.17
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Spruce Biosciences Inc
is for
a loss of 32 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spruce
Biosciences Inc is $2.50​, above​ its last closing price
of $0.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.29       -0.29      -0.28     Beat    3.2
 Jan. 1 2024   -0.39       -0.39      -0.24     Beat    37.8
 Sep. 30 2023  -0.36       -0.35      -0.30     Beat    15.1​
 Jan. 1 0001   -0.39       -0.39      -0.32     Beat    18.4
 ​​Mar.        -0.33       -0.36      -0.40     Missed  -10.4
 31 2023                                                
 Dec. 31 2022  -0.56       -0.53      -0.47     Beat    11.3​
 Sep. 30 2022  -0.54       -0.53      -0.48     Beat    10.3
 Jun. 30 2022  -0.53       -0.52      -0.51     Beat    2.9
 This summary was machine generated August 9 at 15:52 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)